Mucormycosis: A Case Report and Review of Literature

  • Lee, Guem-Sug (Department of Dentistry, Chonnam National University Hwasun Hospital) ;
  • Lee, Kyung-Hwa (Department of Pathology, Chonnam National University Hwasun Hospital) ;
  • Kim, Byung-Gook (Department of Oral Medicine, School of Dentistry, Chonnam National University) ;
  • Im, Yeong-Gwan (Department of Oral Medicine, Chonnam National University Dental Hospital)
  • Received : 2014.01.28
  • Accepted : 2014.02.15
  • Published : 2014.03.30


Mucormycosis is a rare but fatal fungal infection with low survival rate in immune-compromised patients. It is caused by a fungus belonging to the Mucoraceae family of the Zygomycetes class. Mucormycosis is classified as rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, disseminated, and miscellaneous types according to its clinical manifestations. Early diagnosis and treatment along with correction of the underlying medical condition is important for favorable results. This case presentation describes mucormycosis involving the anterior maxillary region in a leukemic patient with prolonged neutropenia. The patient benefited from a timely biopsy and immediate treatment with amphotericin B, and was successfully managed with an interdisciplinary team approach consisting of dental and several medical specialists.


  1. Waness A, Dawsari GA, Al Jahdali H. The rise of an opportunistic infection called "Invasive Zygomycosis". J Glob Infect Dis 2009;1:131-138.
  2. Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. Future Microbiol 2012;7:639-655.
  3. Tragiannidis A, Roilides E, Walsh TJ, Groll AH. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis 2012;54:258-267.
  4. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-1075.
  5. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-653.
  6. Tamgadge AP, Mengi R, Tamgadge S, Bhalerao SS. Chronic invasive aspergillosis of paranasal sinuses: a case report with review of literature. J Oral Maxillofac Pathol 2012;16:460-464.
  7. Cohnheim J. Zwei falle von mykosis der lungen. Virchows Arch Path Anat 1865;33:157.
  8. Paltauf A. Mycosis mucorina: ein beitrag zur kenntniss der menschlichen fadenpilzerkrankungen. Virchows Arch Path Anat 1885;102:543-564.
  9. Gregory JE, Golden A, Haymaker W. Mucormycosis of the central nervous system: a report of three cases. Bull Johns Hopkins Hosp 1943;73:405-419.
  10. Rammaert B, Lanternier F, Poiree S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab 2012;38:193-204.
  11. Pfalle MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:S3-S14.
  12. Wu VC, Wang R, Lai TS, Wu KD. Deferoxamine-related fatal nasal-orbital-cerebral mucormycosis. Kidney Int 2006;70:1888.
  13. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011;118:1216-1224.
  14. Adams JG. Emergency medicine: clinical essentials. 2nd ed. Philadelphia: Saunders; 2012. pp. 1483-1490.
  15. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.
  16. Severo CB, Guazzelli LS, Severo LC. Chapter 7: zygomycosis. J Bras Pneumol 2010;36:134-141.
  17. Rangel-Guerra RA, Martinez HR, Saenz C, Bosques-Padilla F, Estrada-Bellmann I. Rhinocerebral and systemic mucormycosis. Clinical experience with 36 cases. J Neurol Sci 1996;143:19-30.
  18. Garg R, Gupta VV, Ashok L. Rhinomaxillary mucormycosis: a palatal ulcer. Contemp Clin Dent 2011;2:119-123.
  19. Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope 1980;90:635-648.
  20. Gonzalez Ballester D, Gonzalez-Garcia R, Moreno Garcia C, Ruiz-Laza L, Monje Gil F. Mucormycosis of the head and neck: report of five cases with different presentations. J Craniomaxillofac Surg 2012;40:584-591.
  21. Singh V, Sharma B, Sen R, Agrawal S, Bhagol A, Bali R. Rhinocerebral mucormycosis: a diagnostic challenge and therapeutic dilemma in immunocompetent host. J Oral Maxillofac Surg 2012;70:1369-1375.
  22. Viterbo S, Fasolis M, Garzino-Demo P, et al. Management and outcomes of three cases of rhinocerebral mucormycosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:e69-e74.
  23. Jung SH, Kim SW, Park CS, et al. Rhinocerebral mucormycosis: consideration of prognostic factors and treatment modality. Auris Nasus Larynx 2009;36:274-279.
  24. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. 7th ed. Philadelphia: Saunders; 2012. pp. 631-642.
  25. Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 2011;11:301-311.
  26. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009;48:1743-1751.
  27. Laza-Stanca V, Reid L, Watson JD, Williamson EC. Successful treatment of cutaneous zygomycosis with extensive surgical debridement and oral posaconazole in an immunocompetent patient. J Plast Reconstr Aesthet Surg 2012;65:1259-1261.
  28. Lee HJ, Kwon JC, Kim SH, et al. Posaconazole treatment in Korea: single-center experience over 5 years. Yonsei Med J 2013;54:1234-1240.
  29. Leitner C, Hoffmann J, Zerfowski M, Reinert S. Mucormycosis: necrotizing soft tissue lesion of the face. J Oral Maxillofac Surg 2003;61:1354-1358.

Cited by

  1. An Interesting Case of a 57-Year-Old Male with an Upper Gastrointestinal Bleeding and Obstructive Uropathy with Bilateral Hydronephrosis Diagnosed with Systemic Mucormycosis vol.2018, pp.2090-6633, 2018,